Expand LXRX Menu
LXRX MENU

LXRX Latest Press Releases

-- March 28, 2025 --

Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851 Globe Newswire 7:30 AM

-- March 7, 2025 --

Lexicon Pharmaceuticals to Present at the Leerink Partners Global Healthcare Conference 2025 Globe Newswire 8:30 AM

-- March 6, 2025 --

Lexicon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates Globe Newswire 4:00 PM

-- March 4, 2025 --

Lexicon Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 6, 2025 Globe Newswire 4:15 PM

-- March 3, 2025 --

Lexicon Pharmaceuticals Announces Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain Globe Newswire 7:00 AM

-- March 2, 2025 --

Lexicon Pharmaceuticals to Announce Topline Results from Phase 2b PROGRESS Study Evaluating Pilavapadin (LX9211) in Adults with Diabetic Peripheral Neuropathic Pain Globe Newswire 4:13 PM

-- February 18, 2025 --

Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE) Globe Newswire 8:00 AM

-- January 21, 2025 --

Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain Globe Newswire 8:00 AM

-- January 2, 2025 --

Lexicon Appoints Scott Coiante as Chief Financial Officer Globe Newswire 8:00 AM

-- December 20, 2024 --

Lexicon Announces Receipt of Complete Response Letter for Zynquista (sotagliflozin) Globe Newswire 4:30 PM

-- November 26, 2024 --

Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) Globe Newswire 8:00 AM

-- November 25, 2024 --

Lexicon Pharmaceuticals to Participate in December Investor Conferences Globe Newswire 4:15 PM

-- November 22, 2024 --

Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA Globe Newswire 7:32 AM

-- November 20, 2024 --

Lexicon Appoints Ivan H. Cheung to Board of Directors Globe Newswire 4:10 PM

-- November 14, 2024 --

Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association's (AHA) Sessions 2024 in Chicago Globe Newswire 8:00 AM

-- November 12, 2024 --

Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update Globe Newswire 4:05 PM

-- November 6, 2024 --

Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference Globe Newswire 8:00 AM

-- November 5, 2024 --

Published Data in Journal of American Society of Nephrology Highlights Findings on Efficacy and Safety of Sotagliflozin for People With Type 1 Diabetes and Chronic Kidney Disease Globe Newswire 4:05 PM
Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024 Globe Newswire 8:00 AM

-- November 4, 2024 --

Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss Globe Newswire 8:00 AM